相关实验视频
Updated: May 16, 2025

11:51
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
11.8K
发现了新的四基诺林衍生物作为强效,选择性和口服可用的AR抗剂
Leer Yuan1, Jianing Liao1, Yiyang Qin1
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
European journal of medicinal chemistry
|April 6, 2025
概括
研究人员优化了四基诺林衍生物AT2成为一种强大的雄激素受体 (AR) 抗剂C2. 这种新的C2化合物在前列腺癌 (PCa) 治疗中表现有前途,因为其有效性和改善的药理动力学特性.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 雄激素受体 (AR) 抗剂对于前列腺癌 (PCa) 治疗至关重要.
- 以前的AR抗剂AT2具有较差的药理动力学特性,限制了其临床应用.
研究的目的:
- 为了优化四基诺林支架,以改善AR对抗性.
- 为PCa疗法发现新型AR抗剂,具有增强的功效和药物动力学特征.
主要方法:
- 在AT2脚手架的系统结构修改.
- 在体外测试以确定AR抗剂的强度 (IC50) 和选择性.
- 基于细胞的测定测量LNCaP细胞增殖和PSA蛋白质表达.
- 对AR突变 (ARF877L/T878A) 的疗效和口服生物可用性的评估.
主要成果:
- 一种新的四基诺林衍生物C2被确定为一种强大的AR抗剂 (IC50=0.019μM).
- C2对其他核受体 (PR,GR,MR) 具有很好的选择性.
- C2显著抑制了LNCaP细胞增殖,并降低了PSA蛋白水平.
- 与现有的药物相比,C2在对抗ARF877L/T878A突变体方面表现出更高的疗效.
- C2显示出极好的口服生物利用性,这表明了潜在的体内疗效.
结论:
- 优化的化合物C2是一种强效和选择性的AR抗剂.
- C2表现出有希望的临床前疗效,包括对抗耐药AR突变.
- C2代表了晚期前列腺癌治疗的潜在治疗候选者.
相关概念视频
Structure-Activity Relationships and Drug Design
463
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
463
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
769
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
769
Antipsychotic Drugs: Typical and Atypical Agents
131
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
131
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
514
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
514
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Drug-Receptor Interaction: Antagonist
2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K

